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Abstract African swine fever virus (ASFV) encodes
proteins that manipulate important host antiviral mecha-
nisms. Bioinformatic analysis of the ASFV genome
revealed ORF I329L, a gene without any previous func-
tional characterization as a possible inhibitor of TLR sig-
naling. We demonstrate that ORF I329L encodes a highly
glycosylated protein expressed in the cell membrane and
on its surface. I329L also inhibited dsRNA-stimulated
activation of NFjB and IRF3, two key players in innate
immunity. Consistent with this, expression of I329L pro-
tein also inhibited the activation of interferon-b and CCL5.
Finally, overexpression of TRIF reversed I329L-mediated
inhibition of both NFjB and IRF3 activation. Our results
suggest that TRIF, a key MyD88-independent adaptor
molecule, is a possible target of this viral host modulation
gene. The demonstration of an ASFV host evasion mole-
cule inhibiting TLR responses is consistent with the ability
of this virus to infect vertebrate and invertebrate hosts, both
of which deploy innate immunity controlled by conserved
TLR systems.
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Introduction
African swine fever virus (ASFV) is a lethal haemorrhagic
pathogen of domestic pigs. In its natural mammalian hosts,
the Warthog and Bushpig, however, the virus is persistent,
non-pathogenic and transmitted by an invertebrate vector,
the soft tick. The virus may therefore be considered as
a veterinary model for recently emerged haemorrhagic
infections.
AFSV is an enveloped DNA virus with icosahedral
morphology that is now classiﬁed as the only member of a
new virus family, Asfarviridae [1]. It exhibits a charac-
teristic genomic structure, large numbers of novel genes
and a cytoplasmic replication strategy, and, in contrast to
all other DNA viruses, this arbovirus, infects both verte-
brate (swine) and invertebrate (tick) hosts. The ability of
the virus to infect macrophages and to persist in its natural
hosts, and in domestic pigs, which recover from infection
with less virulent isolates, shows that the virus has effective
mechanisms to evade host defense systems, in particular,
innate immunity. It is estimated that half to two-thirds of
the approximately 150 genes encoded by ASFV do not
have known viral or cellular homologs [2]. Most of the
structural proteins and enzymes have been identiﬁed, but
many of these non-homologous genes have no homology to
known proteins or enzymes. Therefore, we hypothesize that
some of these genes have evolved for, or may be involved
in, host evasion. Such genes provide a source of potentially
valuable tools for understanding virus pathogenesis and for
identifying novel aspects of the vertebrate immune system.
The fact that ASFV has adapted to infect both mam-
malian macrophages and an invertebrate tick host suggests
that this virus may have evolved immune evasion genes
focused on innate immunity, more speciﬁcally, for
manipulation of the Toll-like receptor (TLR) signaling
system, which is conserved in both mammals and arthro-
pods. Moreover, there is abundant expression of TLRs in
macrophages, where they play a critical role in the
detection of viral infections, leading to the inﬂammatory
response and induction of an interferon (IFN)-mediated anti-
viral state in infected and neighboring cells [3]. Under some
circumstances, however, uncontrolled activation of macro-
phages leads to undesirable pathological consequences.
To date, there are at least 13 distinct mammalian TLRs,
all sharing similarities in their extracellular and intracel-
lular domains, in particular, the conserved intracellular
Toll/IL-1 receptor (TIR) domain [4, 5]. Dimerization of
TLRs induced by interaction with the corresponding
ligands initiates the intracellular signaling cascade, fol-
lowed by recruitment of intracellular adaptor proteins to
their dimerized intracellular domains [6]. Among the
adaptor proteins, myeloid differentiation primary response
gene (MyD88) and TIR-domain-containing adaptor-
inducing interferon-b (TRIF) are critical for signaling, and
hence, TLR signaling falls into the MyD88-dependent and
TRIF-dependent pathways [7, 8], both terminating in
activation of the transcription factors nuclear factor jB
(NFjB) and activator protein-1 (AP-1).
Binding to each TLR induces common effects, such as
induction of inﬂammatory cytokines and chemokines and
more speciﬁc and restricted activities, such as the induction
of interferon-b (IFN-b). In turn, IFN-b ampliﬁes the IFN
response and the development of antiviral activity, thus
contributing to an important defense against viral infec-
tions [9]. The transcription factors interferon regulatory
factor-3 (IRF-3) and interferon regulatory factor-7 (IRF-7)
are master regulators of type I IFN activation and partici-
pate in both the TLR-dependent and -independent path-
ways of innate immune responses to viral pathogens [10].
Type I IFNs not only induce an antiviral state in most cells
but also have diverse functions in the development of
adaptive immunity. The existence of several mechanisms
in the immunocompetent host to avoid infections by
pathogens has provided the selective pressure for suc-
cessful viral pathogens to acquire strategies during evolu-
tion to evade the host immune responses [11], in particular
for inhibiting and regulating TLR function, with several
targeting the MyD88-dependent pathway [12].
Viral infections are frequently sensed by TLR3, which
detects dsRNA produced during replication of both DNA
and RNA viruses. MyD88-independent signaling through
the TLR3 pathway is initiated by the recruitment of the
adaptor TRIF, leading to the subsequent production of
inﬂammatory cytokines and type I IFNs and the up-regu-
lation of co-stimulatory molecules. The importance of
TLR3 signaling is emphasized by the fact that it is a target
for immune evasion by viruses [13], for example, vaccinia
virus A52R [14–16] and A46R [14, 17] proteins or hepa-
titis C virus (HCV) NS3/4A protease [18, 19]. Downstream
of TRIF, Sterile-alpha and Armadillo motif-containing
protein (SARM), another cellular molecule with a TIR
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MyD88-independent pathways [20]. Viruses may beneﬁt
from disrupting TLR signaling, and indeed it has been
suggested that vaccinia virus directly engages TLRs [21,
22]. Taking into account the complexity of pathogen rec-
ognition receptor (PRR) signaling in the innate immune
response, it is likely that viruses have evolved a whole
range of mechanisms targeting different PRRs and at dif-
ferent levels of their signaling pathways. Thus, the study of
virus evasion strategies is not only directly relevant to
understanding virus pathogenesis but can also deﬁne novel
aspects of our own immune system. For example, in HCV
infection, the viral NS3/4, a protease complex targets and
cleaves the interferon promoter stimulator-1 (IPS-1)
adaptor protein to ablate signaling of immune defenses
controlled by IFN a/b. Similarly, the ﬁnding that cleavage
of IPS-1 by NS3/4 releases it from the mitochondrial
membrane revealed that the mitochondrial attachment of
IPS-1 is functionally important [19].
Here, we report a successful search for an ASFV host
evasion gene that inhibits an important component of the
innate immune response controlled by a TLR. A combi-
nation of bioinformatics, biochemical and reporter gene
assays identiﬁed the ORF I329L, a late-expressed protein
[23], which was characterized as a type I transmembrane
protein with homology to TRIF in the C-terminal region
and shown to be capable of inhibiting the TLR3 signaling
pathway through an as yet undeﬁned effect on the critical
intracellular signaling adaptor molecule TRIF.
Materials and methods
Bioinformatic analysis
Full-length sequences of non-assigned ASFV ORFs were
screened for homologies using protein-protein BLAST
from the National Center for Biotechnology Information
(NCBI). Screening for patterns or domains was performed
using InterProScan 17.0 from the European Molecular
Biology Laboratory (EMBL) and Prosite 20.33 databases.
The transmembrane region prediction was performed by
TransMembrane Helix prediction using the Hidden Markov
Models 2.0 (TMHMM) program [24], and 3D-structure
similarities were analyzed with Protein Homology/analogy
Recognition Engine (Phyre) [25]. Multiple sequence
alignments were made with ClustalW2 from the European
Bioinformatics Institute (EBI) website.
Plasmids
Plasmids pcDNA3-HA and pHR-CMV-eGFP were gifts
from Dr. L. Dixon (Institute for Animal Health, Pirbright,
UK) and Dr. Y. Ikeda (University College London, London,
UK), respectively. The pFlag-TRIF- and pCCL5-promoter-
containing plasmids were gifts from Dr. Andrew G. Bowie
(Trinity College, Ireland), pDsRed-Monomer-Golgi and
pDsRed2-ER vectors were purchased from ClonTech (cata-
logue number 632480 and 632409, respectively). The b-gal-
CMV- (b-gal), the NFjB- (pPRD2) and IRF3- and IFN-b-
promoter-containing plasmids were gifts from Dr. S. Good-
bourn (St George’s University, London). The plasmids
expressingTLR3andCD4-TLRschimaeraswereprovidedby
Dr. R. Medhzitov (Yale University, USA).
Cloning of I329L
The ASFV ORF I329L (accession number NP_042833) was
obtained by PCR ampliﬁcation from DNA of the tissue-cul-
ture-adapted non-pathogenic ASFV isolate Ba71V (Uniprot
database, code I329_ASFB7) with primers incorporating
restrictionsitesforBamHIupstreamandEcoRVdownstream
of the ORF and using the high-ﬁdelity enzyme Pfu DNA
polymerase. The primers used were 5’caggatccatgc-
taagggttttcatattttttg3’, 5’ctgatatcctttcttcttgaacatgaaacc3’. The
ampliﬁed product was identiﬁed with ethidium bromide
visualization on an agarose gel based on the expected size of
the amplicon, and the DNA was puriﬁed from the excised
band. The fragment was then cloned into plasmid pcDNA3-
HA, fused in frame with an N-terminal inﬂuenza haemag-
glutinin (HA) peptide tag. The ﬁdelity of the sequence of the
cloned fragment was conﬁrmed by automated sequencing.
For construction of a recombinant lentivirus vector
(pHR-CMV-HA-I329L-eGFP), the I329L gene was excised
from pcDNA3, together with the HA tag, and cloned into
the vector pHR-CMV-eGFP upstream of an internal ribo-
some entry site (IRES)-driven enhanced green ﬂuorescent
protein gene (eGFP).
Cells
Human HEK-293T and murine NIH-3T3 cell lines were
cultured in 5% CO2 at 37C in Dulbecco’s modiﬁed Eagle
medium (DMEM) with GlutaMAX
TM-I and 1000 mg/l
glucose, supplemented with 10% (v/v) heat-inactivated
fetal calf serum (FCS) and 100 U/ml and 100 lg/ml pen-
icillin and streptomycin, respectively (all products from
Invitrogen). The stable cell line 293-hTLR3-HA (HEK-
TLR3), purchased from InvivoGen, was maintained
under the same conditions and cultured in regular DMEM
supplemented with 10 lg/ml blasticidin [26].
Lentivirus production
Lentivirus was produced by transient transfection of HEK-
293T cells with a weight ratio of 3:1:1 of vector to
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FuGENE6(Roche)accordingtothemanufacturer’sinstruc-
tions. Control lentivirus was produced by cotransfection of
the packaging and envelope plasmid together with the
empty pHR-CMV-eGFP plasmid. For production of
recombinant lentivirus expressing I329L, the plasmid pHR-
CMV-HA-I329L-eGFP was used. Supernatants containing
the lentivirus were collected at 48 h and 72 h post-trans-
fection and clariﬁed by centrifugation, and the lentivirus
was collected by ultracentrifugation (125,000 x g, 3 h,
4C). Virus pellets were resuspended in fresh culture
medium, frozen at -80C and titrated by infection of
HEK-293T cells with a dilution factor of 4. Analysis of
lentivirus-infected cells was done by detecting eGFP-
positive cells by ﬂow cytometry at 48 h postinfection (p.i.).
Lentivirus transduction of NIH-3T3 cells with I329L
The NIH-I329L and NIH-eGFP stable cell lines were
produced by lentivirus infection of NIH-3T3 cells with the
recombinant pHR-CMV-HA-I329L-eGFP and empty pHR-
CMV-eGFP (prepared as described in the section ‘‘Cloning
of I329L’’), respectively, using a multiplicity of infection
(m.o.i.) of 10 in DMEM. Analysis of NIH-I329L to
determine the percentage of transduced cells was done by
detecting eGFP-positive cells by ﬂow cytometry at 48 h
post-infection (p.i.), and this was veriﬁed to be greater than
99%.
Antibodies
The antibodies used in this study were as follows: rat
monoclonal high-afﬁnity antibody (clone 3F10) against HA
conjugated with horseradish peroxidase (HRP) (Roche,
12013819001), rabbit polyclonal afﬁnity-puriﬁed antibody
against HA for immunoprecipitation assays (Sigma H6908),
rat monoclonal high-afﬁnity antibody (clone 3F10) against
HA for immunoﬂuorescence assays (Roche, 11867423001),
donkey afﬁnity-puriﬁed anti-rat IgG antibody conjugated
with AMCA (Jakson Immuno Research, 712-155-150),
mouse monoclonal antibody (clone B-5-1-2) against
a-tubulin (Sigma-Aldrich, T6074) and rabbit polyclonal
anti-mouse Immunoglobulins conjugated with HRP (Dako,
P0161).
Immunoblotting
NIH-I329L cells were cultured in 75-cm
2 ﬂasks at 37C,
under 5% CO2, in DMEM with GlutaMAX
TM-I and
1000 mg/l glucose, supplemented with 10% (v/v) heat-
inactivated FCS and 100 U/ml and 100 lg/ml penicillin
and streptomycin, respectively (all products from Invitro-
gen). Cells were lysed in cold lysis buffer (6 M urea,
75 mM NaCl, 1 mM EDTA, 1% (v/v) NP40, 2% (v/v)
glycerol, 1 mM PMSF, 1 lM DTT, 25 mM HEPES, pH
7.4). After protein quantiﬁcation by the Bradford method
using the Bio-Rad Protein Assay reagent, extracts were
boiled (5 min, 100C) with sample buffer (1.7% [w/v]
SDS, 5% [v/v] glycerol, 0.1 M DTT, bromophenol blue
[0.02 mg/ml], 58 mM Tris-HCl, pH 6.8). Proteins were
then separated by 10-12% SDS-PAGE and electroblotted
onto polyvinylidene ﬂuoride (PVDF, BioRad) membranes
and blocked with PBS-5% (w/v) non-fat dried milk for 1 h
at room temperature (RT). The development of the blots to
reveal recombinant viral proteins was performed with a rat
monoclonal high afﬁnity antibody against HA conjugated
with HRP (Roche) by incubating for 1 h at RT or overnight
at 4C, and the identiﬁed molecules were revealed with
ECL chemiluminescent reagents (PerBio Science) accord-
ing to the manufacturer’s instructions. Blots were also
developed with a mouse monoclonal antibody against
a-tubulin (Sigma-Aldrich), followed by rabbit polyclonal
anti-mouse immunoglobulins-HRP (Dako) to provide an
internal control for protein loading.
Immunoprecipitation
Mouse NIH-I329L and mouse NIH-eGFP cells were col-
lected by scraping from 75-cm
2 ﬂasks and lysed using cold
RIPA buffer (6 M Urea, 75 mM NaCl, 1 mM EDTA, 1%
(v/v) NP40, 2% (v/v) glycerol, 1 mM PMSF, 5.5 lg/ml
protease inhibitors (SIGMA) and 1 lM DTT, 25 mM
HEPES, pH 7.4) (1 ml per 7 9 10
6 cells). The resulting
protein extract was centrifuged at 20,000 9 g for 10 min at
4C to remove cellular debris. The supernatant of the
protein extracts was collected and, after determining the
concentration of protein, was pre-cleared by adding 100 ll
of protein G beads. After rotating for 1 h at 4C, the beads
were removed by centrifugation, and the recombinant
I329L was recovered from the supernatant by adding pro-
tein G beads (100 ll) and 5 lg of rabbit polyclonal afﬁn-
ity-puriﬁed anti-HA antibody (Sigma). Following rotation
for 1.5 h at 4C, the beads were then washed twice with
lysis buffer without NP-40 and urea, and ﬁnally heated at
100C for 10 min with loading buffer (2% [w/v] SDS, 2%
[v/v] b-mercaptoethanol, 0.1% [w/v] bromophenol blue,
10% [v/v] glycerol, 50 mM Tris-HCl, pH 6.8) for 10 min,
and centrifuged for 30 sec. The supernatants were then
loaded onto an SDS-PAGE gel (10%).
Cell-surface biotinylation
Cell-surface biotinylation was done using a kit purchased
from Pierce (#21335). One 75-cm
2 ﬂask with transduced
NIH-I329L cells was cultured until the cells reached 95%
conﬂuence. Then, the cells were washed twice with cold
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PBS (0.5 mg/ml) was added to the cells, followed by
incubation on a rocking platform with gentle agitation
(30 min, 4C). To stop the reaction, 500 ll of a ‘‘quench-
ing’’ solution (supplied by the manufacturer without
information) was added to each ﬂask. Cells were then
scraped off, centrifuged, washed with TBS and lysed in
modiﬁed RIPA buffer (1% [v/v] Triton X-100, 0.2% [w/v]
Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 0.2% (w/v)
SDS, 1 mM PMSF, protease inhibitors, 50 mM Tris-HCl,
pH 7.4). The biotinylated surface proteins were recovered
from the detergent lysate with streptavidin beads (Pierce
Kit, #89881) (overnight, 4C, in an orbital shaker). The
streptavidin beads were centrifuged, washed 3 times with
lysis buffer without detergent, and ﬁnally suspended in
100 ll1 9 loading buffer (2% [w/v] SDS, 2% [v/v]
b-mercaptoethanol,0.1%[w/v]bromophenolblue,10%[v/v]
glycerol, 50 mM Tris-HCl, pH 6.8). The samples were
heated (10 min, 100C) and centrifuged, and the superna-
tants were loaded onto 10% SDS-PAGE gel. After elec-
trophoresis, the proteins were transferred to a PVDF
membrane (Bio-Rad) and blocked with 5% non-fat dried
milk (1 h, RT). The biotinylated HA-I329L protein was
revealed with a rat monoclonal high-afﬁnity antibody
against HA conjugated with HRP (Roche), followed by
ECL chemiluminescent reagents (PerBio Science) accord-
ing to the manufacturer’s instructions.
Deglycosylation assay
Lentivirus-transduced NIH-I329L cells were collected, and
the recombinant I329L was immunoprecipitated as
described above. Bound I329L was eluted from the anti-
HA protein G beads by heating (10 min, 100C) in 0.5%
(w/v) SDS with 10% (v/v) b-mercaptoethanol. For degly-
cosylation, the eluted sample was treated with peptide-
N-glycosidase F (PNGaseF) (Roche) or endoglycosidase H
(Endo H) (New England Biolabs) according to the manu-
facturer’s instructions. As controls, the enzymes were
omitted. Proteins were then precipitated with ethanol at
80% (v/v) (overnight, -20C). The pellet was resuspended
in 20 ll of SDS-PAGE loading buffer, heated (10 min,
100C), and loaded onto an SDS-PAGE gel.
Immunoﬂuorescence to demonstrate co-localization
of I329L with ER and Golgi
Mouse NIH-I329L cells were seeded onto coverslips
(pretreated with 1% [v/v] poly-L-lysine) and incubated
overnight at 37C and 5% CO2. For double staining to
reveal the endoplasmatic reticulum and the trans-medial
region of the Golgi apparatus, the cells were transfected
using Lipofectamine 2000 (Invitrogen) with 2 lgo fa
plasmid coding for the ER retention sequence KDEL
(plasmid pDsRed2-ER, Clontech) or coding for a sequence
corresponding to the N-terminal 81 amino acids of human
beta-1,4-galactosyltransferase (GT) (plasmid pDsRed-
Monomer-Golgi, Clontech) fused with the ﬂuorescent red
protein.
After transfection for 24 h, the cells were ﬁxed with
4% (w/v) paraformaldehyde in PBS for 20 min at RT and
then incubated in a blocking solution (PBS containing
0.05% Tween-20 and 5% normal goat serum) (30 min,
RT). The cells were permeabilized using PBS containing
0.1% (v/v) Triton X-100. To detect recombinant I329L, a
primary rat monoclonal high-afﬁnity antibody against HA
diluted in blocking solution was used (1 h, RT), followed
by a donkey afﬁnity-puriﬁed anti-rat IgG antibody con-
jugated with AMCA (1 h, RT). All washes after incuba-
tion with antibody were performed at RT with PBS
containing 0.05% (v/v) Tween-20. Cells were mounted in
Vectashield (Vector Laboratories) and observed under a
ﬂuorescence microscope. HA-I329L is shown with a
green colour for better visual perception. Fluorescent
images were taken with a Leica DMRA2 microscope
equipped with a cooled CCD camera (Leica. Corp.,
Wetzlar, Germany).
Luciferase reporter assays
For the CD4-TLR reporter gene assay, HEK-293T cells
were cultured in 24-well plates at 6x10
4/well, and 24 h
later, they were transfected using Lipofectamine 2000
(Invitrogen) with three plasmids. One, the NFjB-driven
luciferase reporter contained only the positive regulatory
domain, PRD2, of the NFjB binding site of the IFN-b
promoter (NFjB) (100 ng), the second contained b-gal-
CMV (b-gal) (25 ng), and the third chimeric plasmid
contained a CD4 extracellular domain co-ligated upstream
of a TLR1 (CD4-TLR1) or TLR3 (CD4-TLR3) intracel-
lular domain (50 ng). The effect of the co-transfection of
the I329L gene cloned into the pcDNA3 plasmid
(pcDNA3-I329L) (300 ng) provides an assay for interfer-
ence of the viral protein with the TLR signaling pathway
[27]. Empty pcDNA3 served as the negative control
(pcDNA3). After incubating for 48 h at 37C, the cells
were lysed in 100 ll lysis solution (ABX210LM, Promega
Systems) according to the manufacturer’s instructions, and
samples were assayed for both luciferase and b-galactosi-
dase activities. The luciferase activity was normalized to
the b-galactosidase activity from the co-transfected plas-
mid internal control and expressed as luciferase relative to
galactosidase activity. Values are expressed as mean rela-
tive stimulation ± SD (calculated from triplicate determi-
nations). A minimum of three independent assays were
done for each experiment reported.
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transfected with reporter plasmids for IFN-b,N F jB,
CCL5, and the internal control b-gal, and expression
plasmids pcDNA3-I329L or pcDNA3 (negative control),
keeping the total amounts of DNA and equimolar ratios
constant in all assays by adding the appropriate amount of
empty vector. After 48 h, cells were stimulated with
polyinosinic:polycytidylic acid (poly (I:C)) or IL1-b
(PeproTech) or TNF-a (PeproTech) as indicated in the
ﬁgures for 5 hours. The cells were lysed and assayed for
luciferase as described above.
IFN-b reporter assays were also done using HEK-293T
cells ectopically expressing TRIF. Transfections were
performed with equal amounts of DNA mixtures com-
prising 25 ng of TRIF plasmid vector (TRIF), the I329L
plasmid vector (pcDNA3-I329L) (0, 100, 200 and 300 ng),
the IFN-b-reporter plasmids (IFN-b) (100 ng) and the
b-gal internal control plasmid (b-gal) (25 ng). The pcDNA3
negative control was included in the transfection whenever
necessary in order to keep the total amounts of DNA and
equimolar ratios constant in all assays. After 48 h, the cells
were stimulated for 6 hours with poly (I:C) (25 lg/ml)
where indicated, before harvesting the cells. Lysis and
luciferase activity were measured and normalized to the
b-galactosidase activity as described above.
Finally, to determine the impact of intracellular stimu-
lation with poly (I:C), HEK-293T cells were transfected
with 300 ng empty vector (pcDNA3) or 300 ng I329L
plasmid vector (pcDNA3-I329L) together with 100 ng of
IFN-b plasmid (IFN-b). After 48 h, the cells were stimu-
lated for 6 h with intracellularly delivered poly (I:C)
(0.5 lg/ml) using Lipofectamine 2000 (Invitrogen). Lysis
and luciferase activity were measured and normalized to
the b-galactosidase activity as described above.
Statistical analysis
Data are expressed as mean ± SD and were analyzed for
signiﬁcance using Student’s T test. P-values are as follows:
*** P\0.005, ** P\0.01 and * P\0.05.
Results
Identiﬁcation of ASFV ORF I329L as a potential
homologue of the TLR family
Bioinformatic analysis of the sequence of pI329L from the
tissue-culture-adapted non-pathogenic ASFV isolate
Ba71V (Uniprot database code I329_ASFB7), which grows
in a variety of commonly used ﬁbroblast cell lines, reveals
a type I membrane structure with a 17-amino-acid signal
peptide (amino acids 1-17), followed by an N-terminal
extracellular domain (amino acids 18-239), a transmem-
brane domain (amino acids 240-260), and a 69-amino-acid
C-terminal intracellular domain (amino acids 261-329). A
number of potential glycosylation sites were indicated, at
amino acids 32, 39, 44, 76, 82, 101, 185, and 219. Simple
sequence examination of the sequence database did not
show any gene similar to I329L; however, after multiple
alignments with several TLR proteins, a weak but inter-
esting alignment between I329L and TLR from Drosophila
melanogaster was revealed. Importantly, the intracellular
domain of I329L aligned with BOX1 and BOX2 regions of
the human TIR-like domain of TLR3 (Fig. 1A), with a
sequence similarity of 35% to TLR3 in BOX1 (Fig. 1B).
Furthermore, the BOX2 of TLR3 also showed similarities
with the I329L intracellular domain (Fig. 1C). Finally, the
conserved extracellular region with leucine-rich repeats
(LRRs) is an important motif for interaction between pro-
teins and is common to several TLRs. Although the
observed similarity was admittedly weak, we nonetheless
decided to clone and test I329L for its impact on poly (I:C)-
stimulated innate immunity in reporter assays (see below).
The cellular distribution of ASFV ORF I329L is
consistent with ER, Golgi and plasma membrane
localization
Bioinformatic analysis and demonstration of extensive
glycosylation suggested that the I329L protein was a typ-
ical transmembrane protein. This possibility was conﬁrmed
in I329L-lentivirus-transduced NIH-3T3 cells (NIH-I329L)
by immunoﬂuorescence and cell-surface labelling. For
immunoﬂuorescence of I329L, the I329L protein was
detected with a rat monoclonal high-afﬁnity antibody
(clone 3F10) against HA, followed by a donkey afﬁnity-
puriﬁed anti-rat IgG antibody conjugated with AMCA.
Co-detection of the endoplasmic reticulum (ER) and Golgi
apparatus was achieved by simultaneously transfecting the
cells with two marker plasmids: one coding for red-ﬂuo-
rescent protein (dsRed) fused with the KDEL sequence in
order to target ER (plasmid pDsRed2-ER) and the other
coding for dsRed fused with an integral protein of the
Golgi apparatus (plasmid pDsRed-Monomer-Golgi). As
can be seen, the cellular distribution of I329L corresponds
to that of the markers for ER and Golgi (Fig. 2A and B),
indicating that I329L passes through the secretory pathway.
Finally, since the intracellular secretory pathway frequently
culminates the incorporation of glycoproteins into the cell
membrane, viable NIH-I329L-transduced cells were sur-
face-biotinylated. Subsequent immunoprecipitation with
streptavidin and western blotting with anti-HA to detect
I329L conﬁrmed the surface expression of I329L in the
transduced cells (Fig. 2D).
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protein
Expression of HA-I329L in NIH-3T3 cells was accom-
plished by transduction with HA-I329L recombinant len-
tivirus (NIH-I329L). The protein immunoprecipitated with
anti-HA antibody migrated in SDS-PAGE with an apparent
molecular weight of *50 kDa, signiﬁcantly larger than the
molecular weight predicted from the amino acid sequence
alone (Fig. 2C, lanes b and d), thus raising the possibility
of extensive glycosylation, as indeed is suggested by bio-
informatic predictions. Therefore, the recombinant I329L
protein was immunoprecipitated from NIH-I329L cells and
digested with two endoglycosidases, PNGase F, which
digests high-mannose, hybrid and complex types of oli-
gosaccharides, and endoglycosidase H (EndoH), which
digests only high-mannose and hybrid types of oligosac-
charides. Digestion with EndoH and PNGase F yielded
recombinant proteins that migrated with a molecular mass
of *37 kDa (Fig. 2C, lane a), and *36 kDa (Fig. 2C, lane
c), respectively, thus conﬁrming that the I329L protein is
extensively glycosylated. Furthermore, the molecular
weight observed for the sample after digestion with
PNGase F was lower than after digestion with Endo H,
suggesting that I329L has a small number of glycans of the
complex type.
ASFV ORF I329L inhibits TLR3 signaling
An important sensor of viral infections is TLR3, which
detects dsRNA and signals through a MyD88-indepen-
dent pathway. In order to demonstrate that I329L was
interfering with TLR3 signaling, we used two entirely
different experiments. In the ﬁrst approach, we used a
CD4-TLR assay focusing on an NFjB-driven luciferase
reporter. These CD4-TLR constructs comprise the
murine CD4 extracellular domain co-ligated to the
cytoplasmatic domain of a human TLR. The extracel-
lular CD4 domain dimerizes spontaneously, resulting in
dimerization of the intracellular TLR domain and thus
constitutive activation of NFjB, which is detected
using the simultaneously transfected luciferase reporter
plasmid. Using this system, expression of I329L was
found to inhibit the induction of the NFjB-dependent
reporter gene signal (Fig. 3A). Negative controls con-
sisted of plasmid pcDNA3 coding for H171R, a known
structural viral protein of ASFV, instead of the I329L
gene, and a CD4-TLR1 construct instead of CD4-TLR3
(Fig. 3A).
As the synthetic dsRNA analogue polyinosine-poly-
cytidylic acid (poly (I:C)) activates cells via TLR3, in the
second system, we also tested the effect of I329L on TLR3-
dependent NFjB activation induced by poly (I:C). Cells
(HEK-293T) were co-transfected with a construct encod-
ing TLR3, the luciferase reporter containing the NFjB
(PRD2) binding sequence, and the plasmid containing
the cloned ASFV I329L gene. The cells were stimulated
with increasing concentrations of poly (I:C) (0, 5, 25,
and 50 lg/ml). The vector of the I329L gene without
an insert (pcDNA3) was used as negative control. This
TLR3-dependent activation of NFjB in HEK-293T cells
expressing TLR3 was inhibited by the ASFV gene I329L at
all concentrations of the ligand, poly (I:C), that were tested
(Fig. 3B). Thus, I329L was shown by two independent
approaches to inhibit the TLR3-mediated activation of
NFjB.
Fig. 1 Homology with TLR3
in the intracellular domain of
ASFV protein I329L. The
analysis presented here was
performed with ClustalW2. 1A)
Sequence of the intracellular
domain of I329L (amino acid
residues 260 to 329) indicating
the predicted BOX1 and BOX2
regions. 1B) Predicted TIR-like
domain in the BOX1 domain of
I329L has sequence homology
with known proteins containing
the BOX1 TIR domain. 1C)
Predicted TIR-like domain in
the BOX 2 domain of I329L.
Details are in Materials and
methods
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induction of poly (I:C)-stimulated activation of NFjB
and IRF3
To conﬁrm and further explore the mechanisms of
I329L-mediated inhibition of TLR3 activation, human
embryonic kidney ﬁbroblasts (HEK-293T) stably
expressing TLR3 (HEK-TLR3) were transfected together
with an NFjB luciferase reporter plasmid (NFjB) and
stimulated with poly (I:C) or IL-1b. As can be seen, the
poly (I:C)-stimulated activation of NFjB via the estab-
lished TLR3 pathway was inhibited by expression of
I329L (Fig. 4A). Activation of NFjB can occur either
dependently or independently of the MyD88 adaptor
molecule. However, the absence of an effect on the IL-1
receptor pathway excludes the possibility that I329L
modulates TLR signaling by interacting with the adaptor
molecule MyD88. Finally, we failed to ﬁnd any inhibi-
tory effect of I329L on NFjB activation stimulated by
TNF-a, indicating that I329L does not have impact on
the NFjB activation pathway via molecules other than
those downstream of TLR ligation. Taking these results
together suggests that I329L acts upstream of the IjB
kinase (IKK-a/IKK-b/IKK-c) complex, which in the case
of TLR3 signalling could be TRIF, a possibility explored
below.
Fig. 2 ASFV protein I329L is highly glycosylated and localizes to
cell membranes. 2A) I329L protein distribution is consistent with
endoplasmic reticulum localization. Lentivirus-transduced NIH-
I329L cells were transfected with plasmid pDsRed2-ER to localize
the protein to the ER (red, left) and then co-stained with a rat
monoclonal high-afﬁnity antibody against the HA, followed by a
donkey afﬁnity-puriﬁed anti-rat IgG antibody conjugated with AMCA
(left, middle). The colocalization is evident in the merged image
(right panel). 2B) I329L protein distribution is consistent with
Golgi localization. The NIH-I329L cells were transfected with
plasmid pDsRed-Monomer-Golgi to localize the protein to the Golgi
(red, left) and then co-stained with a rat monoclonal high-afﬁnity
antibody against the HA, followed by a donkey afﬁnity puriﬁed anti-
rat IgG antibody conjugated with AMCA (left, middle). The
colocalization is evident in the merged image (right panel). 2C)
The I329L protein was immunoprecipitated from lysates from the
lentivirus-transduced NIH-I329L cell line with rabbit anti-HA
antibodies bound to protein G beads. The bound protein was eluted
and digested with EndoH (a) or PNGase (c) and examined by SDS-
PAGE. Controls samples were treated with only EndoH buffer (b) or
only PNGase buffer (d). 2D) I329L protein is expressed at the cell
surface. Biotinylated surface proteins from biotynylated NIH-I329L
cells were collected with streptavidin beads, loaded onto a 10% SDS-
PAGE gel and transferred to PVDF membranes, and I329L was
revealed with a rat monoclonal antibody against HA conjugated with
HRP (band in lane NIHI329L on the left). Lane NIHeGFP represents
NIH-3T3 cells transduced with the empty lentivirus. Details are in
Materials and methods
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123Signal transduction initiated through TLR3 ultimately
diverges into two signaling branches, leading to activation
of NFjB and IRF3. In order to determine whether I329L
also inhibits activation of IRF3, HEK-TLR3 cells were co-
transfected with I329L (pcDNA3) and a reporter plasmid
containing the promoter of IRF3 (IRF3) and then stimu-
lated with poly (I:C). As can be seen (Fig. 4B), in the
presence of I329L, activation of the IRF3 promoter was
signiﬁcantly reduced.
I329L ASFV ORF inhibition of activation of IRF3
and subsequent expression of IFN-b and CCL5
responses
As TLR3 activates and programs interferon and chemokine
expression through the coordinated activation of IRF3 and
NFjB[ 28, 29], we next examined the effect of I329L on
the activation of CCL5 expression using an appropriate
reporter plasmid. We also extended the previously pre-
sented I329L-mediated inhibition of the NFjB-restricted
PRD2 by using a reporter plasmid containing the entire
IFN-b sequence. The rationale for this was that inhibition
of activation of NFjB and IRF3 is predicted to inhibit
induction of IFN-b and chemokine responses, two major
effectors of the antiviral response induced by TLR3.
As can be seen, poly (I:C)-induced CCL5 activation
from HEK-293T cells stably expressing TLR3 (HEK-
TLR3) was inhibited by I329L (Fig. 5A). Moreover, poly
(I:C)-induced IFN-b activation was also inhibited by
I329L in HEK-TLR3 cells (Fig. 5B). Both results are
consistent with an I329L-mediated inhibition of an
MyD88-independent activation pathway [30]a n dr a i s e
the possibility that I329L targets TRIF, as TRIF is the
only known adaptor protein that interacts with TLR3 and
mediates induction of IFN-b through activation of NFjB
and IRF3.
The CCL5 promoter is under the control of the PRD2
and ISRE domains (binding NFjB and IRF3, respec-
tively), the cAMP responsive element (CRE), AP-1, the
gamma interferon activation site (GAS), the nuclear
factor of activated T-cells (NFAT) and CCAAT/enhan-
cer-binding protein (C/EBP) domains (binding proteins
c-Jun/activating transcription factor 2 (ATF2), Fos/c-Jun,
signal transducer and activator of transcription (STAT),
NFAT and C/EBPb. In our experimental system, the
induction of CCL5 and IFN-b is the consequence of a
poly (I:C)-stimulated MyD88-independent activation of
TLR3. Thus, the possibility of an MyD-88-dependent,
IRF5-mediated activation of CCL5 transcription can be
excluded.
The possibility that I329L inhibits IFN-b activation
induced intracellularly via a receptor other than TLR3 was
investigated by introduction of poly (I:C) into HEK-TLR3
cells. Interestingly, there was no effect of I329L on IFN-b
activation via an intracellular poly (I:C) stimulus (Lipo-
fectamine-mediated poly (I:C) transfection) (Fig. 5C), and
Fig. 3 I329L inhibits NFjB activation by TLR3. 3A) I329L
inhibits activation of NFjB. HEK-293T cells were transfected with
constitutively active CD4-TLR plasmids (50 ng CD4-TLR1 or CD4-
TLR3) in the presence of 300 ng of I329L plasmid (pcDNA3-I329L),
100 ng of NFjB reporter plasmid (NFjB) and 25 ng of b-gal reporter
plasmid (b-gal) (black bars) and incubated for 48 h prior to reporter
assays. The negative controls were the plasmid vector without insert
(pcDNA3) (white bars) or with the control H171R insert (pcDNA3-
H171R) (grey bars). 3B) I329L inhibits poly (I:C)-dependent
activation of NFjB. HEK-293T cells were co-transfected with
plasmid vectors encoding 50 ng TLR3 (TLR3), 100 ng NFjB
reporter plasmid (NFjB), 300 ng ASFV I329L gene (pcDNA3-
I329L) and 25 ng of b-gal reporter plasmid (b-gal) (black bars).
Negative and positive controls were the plasmid vector of I329L gene
without an insert (pcDNA3) and TLR3 (grey bars), and the TLR3
plasmid alone (white bars). The cells were stimulated with poly (I:C)
at the concentration indicated. Luciferase activity was normalized to
the b-galactosidase activity obtained with the co-transfected b-gal
plasmid internal control. Standard deviations are shown by error bars.
Details are in Materials and methods
A novel TLR3 inhibitor encoded by African swine fever virus 605
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is mediated via intracellular receptors such as melanoma
differentiation associated gene 5 (MDA-5) or retinoic-acid-
inducible protein I (RIG-1).
Taken together, these results suggest that I329L inhibits
induction of promoters that are known to contain NFjBo r
IRF3 binding sites via the TLR3 pathway and not via
intracellular receptors like MDA-5 and RIG-I.
Fig. 4 I329L inhibits NFjB and IRF3 activation through an
MyD88-independent pathway. 4A) I329L inhibits activation of
NFjB via Poly I:C but not TNF-a or IL-1. HEK-TLR3 cells were
co-transfected with 300 ng of empty plasmid vector (pcDNA3) or
300 ng of the same plasmid vector encoding I329L (pcDNA3-I329L),
together with 100 ng of the NFjB luciferase reporter plasmid (NFjB)
and 25 ng of b-galactosidase reporter plasmid (b-gal), and cultured
for 48 h. At 6 h before harvesting, cells were not stimulated (white
bars), or stimulated with IL-1b (100 ng/ml) (grey bars), TNF-a
(100 ng/ml) (hatched bars) or poly (I:C) (25 lg/ml) (black bars). The
NFjB reporter gene activity was then measured. 4B) I329L inhibits
activation of IRF3. HEK-TLR3 cells were transfected with 300 ng
empty vector (pcDNA3) or 300 ng of the same plasmid encoding
I329L (pcDNA3-I329L) together with 100 ng of IRF3 (IRF3) and
25 ng of b-galactosidase reporter plasmids (b-gal), and 6 h before
harvesting, cells were stimulated extracellularly with 25 lg/ml poly
(I:C). Luciferase activity was normalized to the b-galactosidase
activity given by the co-transfected b-gal plasmid internal control.
Standard deviations are shown by error bars. Details are in Materials
and methods
Fig. 5 I329L inhibits activation of CCL5 and IFN-b promoter.
5A) I329L inhibits activation of CCL5. HEK-TLR3 cells were
transfected with 300 ng empty plasmid vector (pcDNA3) or 300 ng
I329L plasmid vector (pcDNA3-I329L) together with 100 ng of
CCL5 reporter plasmid vector (CCL5). Six h before harvesting, cells
were stimulated extracellularly with 25 lg/ml poly (I:C). 5B) I329L
inhibits activation of IFN-b. HEK-TLR3 cells were transfected with
300 ng empty vector (pcDNA3) or 300 ng of I329L plasmid vector
(pcDNA3-I329L) together with 100 ng of IFN-b plasmid vector (IFN-
b). Six h before harvesting, cells were stimulated extracellularly with
25 lg/ml poly (I:C). 5C) I329L does not inhibit intracellular IFN-b
activation independently of TLR3. HEK-293T cells were transfec-
ted with 300 ng empty vector (pcDNA3) or 300 ng I329L plasmid
vector (pcDNA3-I329L) together with 100 ng of IFN-b plasmid
reporter (IFN-b). Six h before harvesting, cells were stimulated
intracellularly using Lipofectamine 2000 with 0.5 lg/ml poly (I:C).
Luciferase activity was normalized to the b-galactosidase activity
obtained with the cotransfected b-gal plasmid internal control.
Standard deviations are shown by error bars. Details are in Materials
and methods
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123Reversal of ASFV-ORF-I329L-mediated inhibition
of the activation of NFjB and IFN-b promoters
by overexpression of TRIF
Activation of the TLR3-TRIF signaling pathway not only
induces cytokines, co-stimulatory molecules and antimi-
crobial peptides that are induced by all TLRs but also
antiviral type I interferon and speciﬁc chemokines includ-
ing IP-10 and CCL5 [28, 29].
A direct effect of I329L on TRIF signaling was dem-
onstrated using HEK-TLR3 cells transfected with TRIF as,
in the presence of I329L, the IFN-b signaling pathway was
inhibited (Fig. 6A). To further investigate the possible
impact of I329L on TRIF signaling, HEK-TLR3 cells were
simultaneously transfected with I329L (pcDNA3-I329L),
the IFN-b luciferase reporter plasmid (IFN-b) and
increasing quantities of TRIF plasmid (TRIF) and then
stimulated with poly (I:C). As can be seen, overexpression
of TRIF reversed the inhibition of reporter activation
induced by I329L in a dose-dependent manner, consistent
with the hypothesis that the ASFV gene I329L targets
TRIF signaling (Fig. 6B).
Discussion
The necessity to recognize and destroy invading pathogens
has played a crucial role in the evolution of the immune
system of both vertebrates and invertebrates. At the same
time, pathogens and, in particular, viruses have evolved
reciprocal strategies to manipulate the immune system.
Here, we describe a novel gene from African swine
fever virus (ASFV), I329L, which is able to modulate one
of the most critical steps of the innate immune response by
interfering with TLR3-stimulated activation. This may
constitute an advantage for the virus with an impact on
both its vertebrate and invertebrate hosts, pigs and ticks,
respectively. Conventional bioinformatic analysis of the
sequence of I329L predicted a putative type 1 transmem-
brane protein with an intracellular domain followed by a
transmembrane region and an extracellular domain with
nine potential glycosylation sites and leucine-rich repeats
(LRRs). Both TLR3 and I329L are type I transmembrane
proteins with 20% of their sequence intracellular and more
than 70% in a highly glycosylated extracellular domain
with LRRs. Interestingly, more detailed analysis revealed
that the intracellular domain of I329L contains a region of
homology with BOX1 and BOX2 of TLR3-TIR domain
(Fig. 1A–C). In addition, the putative intracellular domain
contains a number of intracellular signaling sequences such
as SH2 and SH3 domain binding motifs, a major TRAF2-
binding consensus motif and a CK2 phosphorylation site
(data not shown). In the work mentioned above, we con-
ﬁrmed that ORF I329L codes for a highly glycosylated
protein (Fig. 2C). Signiﬁcantly, TLR3 is one of the most
heavily glycosylated of the TLRs [31], and ORF I329L was
Fig. 6 I329L inhibits activation of the IFN-b promoter at the level
of TRIF. 6A) I329L inhibits TRIF-mediated activation of IFN-b.
Activation of the IFN-b promoter reporter plasmid was induced via
ectopic expression of TRIF in HEK-293T cells through transfection
with the TRIF plasmid vector. Transfections were performed with equal
amounts of DNA comprising 25 ng of TRIF plasmid vector (TRIF)
in the presence of increasing amounts of I329L plasmid vector
(100–300 ng) (pcDNA3-I329L) jointly with IFN-b-reporter plasmids
(IFN-b). 6B) Overexpression of TRIF reverses I329L-mediated
inhibition of IFN-b activation. TRIF was ectopically expressed in
HEK-293T cells with increasing amounts of TRIF plasmid vector
(25–100 ng) (TRIF) in the presence of 200 ng of the plasmid vector
coding for I329L (pcDNA3-I329L) simultaneously with 100 ng of IFN-
b-reporter plasmid vector (IFN-b)p l u s2 5n go fb-gal plasmid vector
(b-gal) and after stimulating for 6 hours with 25 lg/ml of poly (I:C)
where indicated, before harvesting the cells. In all cases, luciferase
activity was measured after 48 h. Luciferase activity was normalized to
the b-galactosidase activity obtained with the cotransfected b-gal
plasmid internal control. Standard deviations are shown by error bars.
Details are in Materials and methods
A novel TLR3 inhibitor encoded by African swine fever virus 607
123demonstrated to be expressed in the cell membranes
(Fig. 2A, B) and at the cell surface (Fig. 2D), locations
where many receptor and adaptor molecules involved in
innate immunity have been identiﬁed [32]. Consistent with
this, we showed that I329L inhibited double-stranded-
RNA-stimulated activation of NFjB (Fig. 4A) and IRF3
(Fig. 4B), two key players in the innate antiviral response.
As might be predicted, expression of I329L protein also
inhibited the activation of CCL5 (Fig. 5A) and IFN-b
(Fig. 5B). Finally, IRF3 activation mediated by expression
of TRIF was inhibited by I329L (Fig. 6A), whereas over-
expression of TRIF reverted the inhibition of reporter
activation induced by I329L in a dose-dependent manner
(Fig. 6B). Thus, I329L may be targeting at the level of
TRIF, a key adaptor molecule in the MyD88-independent
pathway. Direct biochemical proof of this has not been
possible, despite many attempts.
Although this is the ﬁrst ASFV gene manipulating TLR
responses to be described, vaccinia virus has evolved two
proteins, A46R and A52R, that are inhibitors of the TIR-
mediated immune response [12].
Based on our experimental data and the bioinformatic
data presented above, some hypothetical models for the
ASFV TLR-based strategies to evade the host defense by
targeting TLR3 were considered. The most immediate
explanation focuses on the intracellular domain of I329L,
with its abundance of signaling motifs—in particular, the
putative TIR homologous region—and the reversion of
I329L-mediated inhibition by overexpression of TRIF. The
latter experiment suggested that the cytoplasmic tail of
I329L might interfere with recruitment of TRIF, an
important adaptor protein involved in the MyD88-inde-
pendent pathway. Similarly, a direct interaction between
the cytoplasmic tail of I329L and TLR3 was suggested by
the observed sequence homology between BOX1 of the
TIR domain and the intracellular region YIPLIPSY
sequence of I329L (Fig. 1B). This conclusion is supported
by the experimental data showing I329L-mediated inhibi-
tion of IRF3 and NFjB activation and the predicted inhi-
bition of induction of expression of CCL5 (Fig. 5A) and
IFN-b (Fig. 5B) induced by externally, but not by inter-
nally, delivered poly (I:C) (Fig. 5C). Finally, the observa-
tion that increasing amounts of I329L were able to inhibit
TRIF-mediated NFjB (Fig. 4A) and IRF3 (Fig. 4B) acti-
vation is consistent with the hypothesis that I329L acts at
the level of TRIF in the signal transduction pathway. Thus,
the possibility that I329L protein interacts with the speciﬁc
intracellular area responsible for TLR3 homodimerization
cannot be excluded, although in most but not all cells,
TLR3 is localized to the endosome and not on the cell
surface. It is worth adding that when the intracellular
domain of ORF I329L is aligned to several TIR domains, it
shows a higher homology to the TLR3-TIR domain than to
other TIR-domain-containing molecules.
The absence of I329L RNA in ASFV-infected cells until
20 hours postinfection, as shown by northern blot analysis
[23], is difﬁcult to reconcile with our ﬁndings; that is, a
virus mechanism such as I329L, evolved to inhibit IFN and
chemokine induction, might be predicted to be expressed
early in virus infection. Thus, it will be important to
measure expression of I329L by a method that is more
sensitive than northern blotting.
In conclusion, the results presented show that ORF
I329L is able to impair the cellular responses controlled by
TLR3 that lead to both IFN-b production and NFjB acti-
vation. The precise mechanism for this inhibition remains
to be elucidated, but our current working hypothesis based
on our observations and the current literature is that the
ORF-I329L-mediated inhibition is intracellular and might
be related to an interaction with TRIF. In view of the major
impact of I329L on innate immunity, its deletion may
provide a rational strategy for construction of an attenuated
deletion mutant vaccine.
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